Search Results - "Java, James J"

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation by Rose, Peter G, Java, James J, Whitney, Charles W, Stehman, Frederick B, Lanciano, Rachelle, Thomas, Gillian M

“…Abstract Objective Conflicting results have been reported for adeno- and adenosquamous carcinomas of the cervix with respect to their response to therapy and…”
Get full text

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study by Ferriss, James S, Java, James J, Bookman, Michael A, Fleming, Gini F, Monk, Bradley J, Walker, Joan L, Homesley, Howard D, Fowler, Jeffrey, Greer, Benjamin E, Boente, Matthew P, Burger, Robert A

“…Abstract Objectives Predictive factors for efficacy of bevacizumab in advanced ovarian cancer have remained elusive. We investigated ascites both as a…”
Get full text

Patient and Physician Perceptions of Virtual Visits for Parkinson's Disease: A Qualitative Study by Mammen, Jennifer R, Elson, Molly J, Java, James J, Beck, Christopher A, Beran, Denise B, Biglan, Kevin M, Boyd, Cynthia M, Schmidt, Peter N, Simone, Richard, Willis, Allison W, Dorsey, E Ray

“…Background and Introduction: Delivering care through telemedicine directly into the patient's home is increasingly feasible, valuable, and beneficial. However,…”
Get more information

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis by Moore, Kathleen N., MD, Java, James J., PhD, Slaughter, Katrina N., MD, Rose, Peter G., MD, Lanciano, Rachelle, MD, DiSilvestro, Paul A., MD, Thigpen, J. Tate, MD, Lee, Yi-Chun, MD, Tewari, Krishnansu S., MD, Chino, Junzo, MD, Seward, Shelly M., MD, Miller, David S., MD, Salani, Ritu, MD, Moore, David H., MD, Stehman, Frederick B., MD

“…Abstract Objective To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on…”
Get full text

Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2 by Bishop, Erin A, Java, James J, Moore, Kathleen N, Walker, Joan L

“…Elderly endometrial cancer patients have worse disease-specific survival than their younger counterparts, but the cause for this discrepancy is unknown. The…”
Get more information

The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients – An analysis of NRG Oncology/Gynecologic Oncology Group trials by Chan, John K., MD, Java, James J., MA, Fuh, Katherine, MD, PhD, Monk, Bradley J., MD, Kapp, Daniel S., MD, PhD, Herzog, Thomas, MD, Bell, Jeffrey, MD, Young, Robert, MD

“…Abstract Objectives To determine the association between timing of adjuvant therapy initiation and survival of early stage ovarian cancer patients. Methods…”
Get full text

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study by Horowitz, Neil S., Larry Maxwell, G., Miller, Austin, Hamilton, Chad A., Rungruang, Bunja, Rodriguez, Noah, Richard, Scott D., Krivak, Thomas C., Fowler, Jeffrey M., Mutch, David G., Van Le, Linda, Lee, Roger B., Argenta, Peter, Bender, David, Tewari, Krishnansu S., Gershenson, David, Java, James J., Bookman, Michael A.

“…Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial…”
Get full text

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study by Rose, Peter G., MD, Java, James J., PhD, Morgan, Mark A., MD, Alvarez-Secord, Angeles, MD, Kesterson, Joshua P., MD, Stehman, Frederick B., MD, Warshal, David P., MD, Creasman, William T., MD, Hanjani, Parviz, MD, Morris, Robert T., MD, Copeland, Larry J., MD

“…Abstract Purpose GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >…”
Get full text

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study by Garcia-Soto, Arlene E, MD, Java, James J, PhD, Nieves Neira, Wilberto, MD, Pearson, J Matthew, MD, Cohn, David E., MD, Lele, Shashikant B, MD, Tewari, Krishnansu S, MD, Walker, Joan L, MD, Alvarez Secord, Angeles, MD, Armstrong, Deborah K, MD, Copeland, Larry J, MD

“…Abstract Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients…”
Get full text

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study by Tewari, Devansu, Java, James J, Salani, Ritu, Armstrong, Deborah K, Markman, Maurie, Herzog, Thomas, Monk, Bradley J, Chan, John K

“…To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer. Data from…”
Get full text

Mixed‐methods content and sentiment analysis of adolescents’ voice diaries describing daily experiences with asthma and self‐management decision‐making by Mammen, Jennifer R., Java, James J., Rhee, Hyekyun, Butz, Arlene M., Halterman, Jill S., Arcoleo, Kimberly

“…Background Accurate symptom assessment remains challenging in teen populations. Little is known of usual symptom/response patterns, and self‐reported paper…”
Get full text

Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study by Bishop, Erin A., Java, James J., Moore, Kathleen N., Spirtos, Nick M., Pearl, Michael L., Zivanovic, Oliver, Kushner, David M., Backes, Floor, Hamilton, Chad A., Geller, Melissa A., Hurteau, Jean, Mathews, Cara, Wenham, Robert M., Ramirez, Pedro T., Zweizig, Susan, Walker, Joan L.

“…Tolerance of and complications caused by minimally invasive hysterectomy and staging in the older endometrial cancer population is largely unknown despite the…”
Get full text

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer by Pitiyarachchi, Omali, Friedlander, Michael, Java, James J., Chan, John K., Armstrong, Deborah K., Markman, Maurie, Herzog, Thomas J., Monk, Bradley J., Backes, Floor, Secord, Angeles Alvarez, Bonebrake, Albert, Rose, Peter G., Tewari, Krishnansu S., Lentz, Samuel S., Geller, Melissa A., Copeland, Larry J., Mannel, Robert S.

“…Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We…”
Get full text

Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236) by Duska, Linda R, Java, James J, Cohn, David E, Burger, Robert A

“…Abstract Background Readmission within 30 days is a measure of care quality. Ovarian cancer patients are at high risk for readmission, but specific risk…”
Get full text

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma by Rose, Peter G., Java, James J., Salani, Ritu, Geller, Melissa A., Secord, Angeles Alvarez, Tewari, Krishnansu S., Bender, David P., Mutch, David G., Friedlander, Michael L., Van Le, Linda, Method, Michael W., Hamilton, Chad A., Lee, Roger B., Wenham, Robert M., Guntupalli, Saketh R., Markman, Maurie, Muggia, Franco M., Armstrong, Deborah K., Bookman, Michael A., Burger, Robert A., Copeland, Larry J.

“…OBJECTIVE:To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian–peritoneal–tubal carcinoma and to develop…”
Get full text

Development and preliminary results of an Electronic Medical Record (EMR)-integrated smartphone telemedicine program to deliver asthma care remotely by Mammen, Jennifer R, Java, James J, Halterman, Jill, Berliant, Marc N, Crowley, Amber, Frey, Sean M, Reznik, Marina, Feldman, Jonathan M, Schoonmaker, Judith D, Arcoleo, Kimberly

“…Technology-based interventions that can function within real-world practice and improve outcomes increasing provider burden are needed, yet few successfully…”
Get more information

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study by Seamon, Leigh G, Java, James J, Monk, Bradley J, Penson, Richard T, Brown, Jubilee, Mannel, Robert S, Oaknin, Anna, Leitao, Mario M, Eisenhauer, Eric L, Long, Harry J, Liao, Shu Y, Tewari, Krishnansu S

“…Background: Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the…”
Get full text

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients by Fuh, Katherine C., Java, James J., Chan, John K., Kapp, Daniel S., Monk, Bradley J., Burger, Robert A., Young, Robert C., Alberts, David S., McGuire, William P., Markman, Maurie, Bell, Jeffrey, Ozols, Robert F., Armstrong, Deborah K., Aghajanian, Carol, Bookman, Michael A., Mannel, Robert S.

“…To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. Ancillary data were pooled and analyzed…”
Get full text

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study by Olawaiye, Alexander B., Java, James J., Krivak, Thomas C., Friedlander, Michael, Mutch, David G., Glaser, Gretchen, Geller, Melissa, O'Malley, David M., Wenham, Robert M., Lee, Roger B., Bodurka, Diane C., Herzog, Thomas J., Bookman, Michael A.

“…To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival…”
Get full text

Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group by Tewari, Krishnansu S, Java, James J, Gatcliffe, Troy A, Bookman, Michael A, Monk, Bradley J

“…Abstract Objective To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced…”
Get full text